US › Healthcare

Cingulate Inc (CING)

US · Healthcare · Biotechnology

$4.90+1.45%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-9.3M

Profit YoY

-141.7%

EPS

$-0.95

EPS estimate

$-0.53

EPS came in at -0.95 against a street estimate of -0.53 — a miss of 79.2%.

Key statistics

Market cap

$64.5M

Forward P/E

0.0

P/B

3.42

Book value

$1.58

EPS (TTM)

$-4.33

52-week high

$11.89

52-week low

$3.16

50-day MA

$4.76

200-day MA

$5.09

Beta

-0.92

Analyst view

Analysts rate Cingulate Inc a buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $23.00.

Shareholding

Insiders

30.54%

Institutions

10.31%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	2.29%
Kestra Advisory Services, LLC	1.12%
Geode Capital Management, LLC	0.75%
Marshall Wace Asset Management Ltd	0.69%
Jane Street Group LLC	0.67%
XTX Topco Ltd	0.40%
BCV Asset Management Inc.	0.38%
Vanguard Fiduciary Trust Co	0.37%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cingulate Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.